News

2013 POZEN News Archive

Keyword Search
 
2015 | 2014 | 2013
DateTitle 
12/23/13POZEN Announces New PA8140/PA32540 PDUFA Date of April 25, 2014
Results of a Pharmacokinetic Study to be Submitted to and Evaluated by FDA During First Quarter 2014 CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec. 23, 2013-- POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that following ongoing interactions with the United States Food & Drug Administration (FDA) concerning its New Drug Application (NDA) for PA8140/PA32540 tablets, the... 
Printer Friendly Version
12/05/13POZEN Clarifies Ex-Dividend Date for Previously Announced Special Cash Distribution
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec. 5, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the ex-dividend date for POZEN’s previously announced $1.75 special cash distribution is December 31, 2013. On November 21, 2013 POZEN announced that its Board of Directors had declared a special cash distribution of $1.75 per share payable to stockholders of record ho... 
Printer Friendly Version
11/21/13POZEN Announces Special Cash Distribution
Return of $1.75 Per Share to All Stockholders of Record as of December 11, 2013 CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 21, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the Board of Directors has declared a special cash distribution of $1.75 per share to all stockholders of record as of the close of business on December 11, 2013, with an expected paym... 
Printer Friendly Version
11/21/13POZEN to Present at the Piper Jaffray 25th Annual Healthcare Conference
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 21, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that John R. Plachetka, Pharm.D., the Company’s Chairman, President and Chief Executive Officer, will present at the Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3, 2013 at 12:30 p.m. (ET) at the New York Palace Hotel. The presentation will be webcast and ... 
Printer Friendly Version
11/19/13POZEN Announces U.S. Rights for VIMOVO® to Be Acquired by Horizon Pharma USA, Inc.
Guaranteed Minimum Royalty Payments to POZEN Key Element of New Deal CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 19, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that AstraZeneca AB and Horizon Pharma USA, Inc. (NASDAQ: HZNP) have entered into an agreement for Horizon to acquire the U.S. rights for VIMOVO® (naproxen / esomeprazole magnesium) delayed release ta... 
Printer Friendly Version
11/06/13POZEN Reports Third Quarter 2013 Results
Exclusive License Agreement for U.S. Rights to PA8140/PA32540 Signed with Sanofi US CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 6, 2013-- POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2013. Recent Corporate Highlights In September, POZEN and Sanofi US announced the signing of an exclus... 
Printer Friendly Version
10/30/13POZEN Announces November 6th Webcast of Third Quarter 2013 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Oct. 30, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release third quarter 2013 results on November 6, 2013, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be a... 
Printer Friendly Version
09/04/13SANOFI US and POZEN sign exclusive license agreement for the commercialization of PA8140/PA32540 tablets in the U.S.
Bridgewater, N.J. AND Chapel Hill, N.C., September 4, 2013 — Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN’s proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet (“PA”), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize ... 
Printer Friendly Version
09/04/13POZEN Announces September 5th Webcast to Discuss the PA8140/PA32540 Exclusive U.S. License Agreement
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sep. 4, 2013-- POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to hold a live webcast on September 5, 2013 at 11:00 a.m. (ET), with a discussion by POZEN management of the PA8140/PA32540 exclusive U.S. license agreement. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for ... 
Printer Friendly Version
08/06/13POZEN Reports Second Quarter 2013 Results
NDA for PA8140/PA32540 Accepted for Review by FDA CHAPEL HILL, N.C.--(BUSINESS WIRE)--Aug. 6, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2013. Recent Corporate Highlights POZEN announced that the U.S. Food and Drug Administration (FDA) accepted for review, the New Drug Application (... 
Printer Friendly Version
07/30/13POZEN Announces August 6th Webcast of Second Quarter 2013 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jul. 30, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release second quarter 2013 results on August 6, 2013, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be ac... 
Printer Friendly Version
06/25/13POZEN’S PA32540 Associated with a Significantly Lower Rate of Endoscopic Gastroduodenal Ulcers as Compared to Aspirin Alone in Patients with Diabetes
Data Presented at the American Diabetes Association’s 73rd Scientific Session CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 25, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented a post-hoc analysis of diabetic subpopulation results from two Phase 3 PA32540 (325 mg enteric-coated (EC) aspirin / 40 mg immediate-release omeprazole) studies at the American Diabetes Association... 
Printer Friendly Version
05/29/13POZEN Announces FDA Acceptance of Filing of New Drug Application for PA32540/PA8140 Tablets
CHAPEL HILL, N.C.--(BUSINESS WIRE)--May. 29, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the New Drug Application (NDA) for PA32540/PA8140. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor (PPI), layered around a pH-s... 
Printer Friendly Version
05/23/13POZEN to Present at the Jefferies 2013 Global Healthcare Conference
CHAPEL HILL, N.C.--(BUSINESS WIRE)--May. 23, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that William L. Hodges, the Company’s Chief Financial Officer and Sr. Vice President, will present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013 at 9:30 a.m. (EDT) in New York City. The presentation will be webcast and available for replay on POZEN’s ... 
Printer Friendly Version
05/08/13POZEN Reports First Quarter 2013 Results
NDA for PA32540/PA8140 Submitted to FDA in Late March CHAPEL HILL, N.C.--(BUSINESS WIRE)--May. 8, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013. Recent Corporate Highlights POZEN announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA... 
Printer Friendly Version
04/30/13POZEN Announces May 8th Webcast of First Quarter 2013 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Apr. 30, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2013 results on May 8, 2013, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be access... 
Printer Friendly Version
04/05/13POZEN Announces Results from a Burden of Cardiovascular Disease Study: a Managed Care Perspective
Presentation at AMCP Demonstrates Cost Reduction When PPI Used in Combination With Aspirin for Both Commercial and Medicare Populations CHAPEL HILL, N.C.--(BUSINESS WIRE)--Apr. 5, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced the results of a POZEN sponsored study at the Academy of Managed Care Pharmacy’s 25th Annual Meeting and Expo on April 4, 2013. Ryan S. Clark, Phar... 
Printer Friendly Version
03/27/13POZEN Submits New Drug Application for PA32540/PA8140
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 27, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of PA32540/PA8140. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor (PPI), layere... 
Printer Friendly Version
03/12/13POZEN Reports European Patent Office Maintains PA/VIMOVO Patent
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 12, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the Opposition Division of the European Patent Office has maintained the granted European patent, EP1411900, entitled Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs, which covers VIMOVO and its PA product candidates. The patent claims maintained in ... 
Printer Friendly Version
03/07/13POZEN to Present at the 25th Annual ROTH Conference
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 7, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that John R. Plachetka, Pharm.D., the Company’s Chairman, President and Chief Executive Officer, will present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013 at 9:00 a.m. (PT), at the Ritz-Carlton Hotel in Laguna Niguel, California. The presentation will b... 
Printer Friendly Version
03/06/13POZEN Reports Fourth Quarter & Year End 2012 Results
NDA Filing for PA32540/PA8140 Expected by Q2 2013 CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 6, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2012. 2012 and Recent Corporate Highlights POZEN is currently preparing a New Drug Application (NDA) for its investiga... 
Printer Friendly Version
02/27/13POZEN Announces March 6th Webcast of Fourth Quarter and Year End 2012 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 27, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2012 results on March 6, 2013, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The w... 
Printer Friendly Version
02/08/13POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference
HONOLULU--(BUSINESS WIRE)--Feb. 8, 2013-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease. These data were presented at the American Heart Association 2013 International St... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.